A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy

PURPOSE: Combination therapy of fosaprepitant, dexamethasone (DEX) and a serotonin (5-HT(3)) receptor antagonist is a standard antiemetic prophylaxis for patients receiving highly emetogenic chemotherapy (HEC). However, the appropriate dose of DEX has not been established in Japan. This study determ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Kumagai, Hozumi, Kusaba, Hitoshi, Yamanaka, Takeharu, Nio, Kenta, Inadomi, Kyoko, Takayoshi, Kotoe, Ito, Mamoru, Tamura, Shingo, Makiyama, Akitaka, Makiyama, Chinatsu, Hirano, Gen, Shibata, Yoshihiro, Shirakawa, Tsuyoshi, Mitsugi, Kenji, Ariyama, Hiroshi, Esaki, Taito, Akashi, Koichi, Baba, Eishi
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6023705/
https://ncbi.nlm.nih.gov/pubmed/29923992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000011042
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados